InfuSystem Eyes Profitable Momentum With Margin Boost and Growth Strategy

Medical‑device company InfuSystem Holdings, Inc. is doubling down on profitability this fiscal year, shifting away from revenue growth alone and steering toward higher margins and disciplined execution. The firm is targeting annual revenue growth in the 6%‑8% range while aiming for an adjusted EBITDA margin of 20% or more. Key to this strategy is stepping up operational efficiency—streamlining billing and analytics, tightening cost control, and focusing resources on the most lucrative segments. The result: in Q3 2024, the company reported year‑over‑year revenue growth of about 11% and expanded its EBITDA margin by 2.8 percentage points. With leadership emphasizing “fewer, better bets” instead of broad expansion, InfuSystem appears poised to convert its investments into stronger cash flow and shareholder value. If execution stays on track, the risk‑reward profile may tilt in favour of investors willing to ride the margin‑expansion wave. #InfuSystem #MarginExpansion #HealthcareGrowth #SmallCapInvesting #SlimScan #GrowthStocks #CANSLIM